Resolution of secondary amyloidosis 14 years after adequate chemotherapy for skeletal tuberculosis.

South Med J

Pulmonary Section, Laboratory Service, and Diagnostic Radiology, HinesVeterans Administration Hospital, Ill.

Published: January 1989

Despite available chemotherapy, survival of patients with skeletal tuberculosis and secondary amyloidosis for more than five years is extremely unusual. We have described a patient with inadequately treated tuberculous osteomyelitis and later concomitant pulmonary tuberculosis and secondary amyloidosis. After a prolonged course of antituberculous chemotherapy, the patient was found to be cured of the tuberculosis and to have complete resolution of the amyloidosis 14 years after the diagnosis.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00007611-198901000-00024DOI Listing

Publication Analysis

Top Keywords

secondary amyloidosis
12
amyloidosis years
12
skeletal tuberculosis
8
tuberculosis secondary
8
resolution secondary
4
amyloidosis
4
years adequate
4
adequate chemotherapy
4
chemotherapy skeletal
4
tuberculosis
4

Similar Publications

The misfolding and amyloid aggregation of proteins have been attracting scientific interest for a few decades, due to their link with several diseases, particularly neurodegenerative diseases. Proteins can assemble and result in insoluble aggregates that, together with intermediate oligomeric species, modify the extracellular environment. Many efforts have been and are devoted to the search for cosolvents and cosolutes able to interfere with amyloid aggregation.

View Article and Find Full Text PDF

Importance: Patients with transthyretin (ATTR) cardiac amyloid infiltration are increasingly diagnosed at earlier disease stages with no heart failure (HF) symptoms and a wide range of cardiac amyloid infiltration.

Objective: To characterize the clinical phenotype and natural history of asymptomatic patients with ATTR cardiac amyloid infiltration.

Design, Setting, And Participants: This cohort study analyzed data of all patients at 12 international centers for amyloidosis from January 1, 2008, through December 31, 2023.

View Article and Find Full Text PDF

Importance: Early detection of brain amyloidosis (Aβ+) is pivotal for diagnosing Alzheimer's disease (AD) and optimizing patient management, especially in light of emerging treatments. While plasma biomarkers are promising, their combined diagnostic value through specific ratios remains underexplored.

Objective: To evaluate the diagnostic accuracy of plasma pTau isoform (pTau181 and pTau217) to Aβ42 ratios in detecting Aβ+ status.

View Article and Find Full Text PDF

Non-Classical Complications of Adult-Onset Still's Disease: A Multicenter Spanish Study.

J Clin Med

January 2025

Department of Pediatric Rheumatology, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Universitat de Barcelona, 08950 Barcelona, Spain.

To investigate the prevalence and clinical spectrum of atypical or non-classical complications in adult-onset Still's disease (AOSD) beyond macrophage activation syndrome (MAS) and to identify factors linked to their occurrence. Multicenter cross-sectional study of AODS cases included in the Spanish registry on Still's disease. This study included 107 patients (67% women), of whom 64 (59.

View Article and Find Full Text PDF

Early therapeutic intervention in high-risk smoldering multiple myeloma (HR-SMM) has shown benefits, however, no studies have assessed whether biochemical progression or response depth predicts long-term outcomes. The single-arm I-PRISM phase II trial (NCT02916771) evaluated ixazomib, lenalidomide, and dexamethasone in 55 patients with HR-SMM. The primary endpoint, median progression-free survival (PFS), was not reached (NR) (95% CI: 57.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!